IC
ZNTL icon

IEQ Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

IEQ Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,229
Closed -$16.5K – 2104
2025
Q4 		$16.5K Sell
12,229
-21,924
-64% -$31.9K ﹤0.01% 1831
2025
Q3 		$51.6K Sell
34,153
-52,147
-60% -$78.2K ﹤0.01% 1799
2025
Q2 		$100K Sell
86,300
-7,620
-8% -$10.1K ﹤0.01% 1717
2025
Q1 		$149K Buy
93,920
+78,805
+521% +$170K ﹤0.01% 1428
2024
Q4 		$45.8K Buy
+15,115
New +$49.5K ﹤0.01% 1299

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

IEQ Capital's ZNTL Position: Q1 2026 in Review

IEQ Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 12,229 shares — an estimated $16.5K sold.

IEQ Capital first reported a position in ZNTL in Q4 2024 and held it in 5 quarters. The position peaked at $149K in Q1 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • IEQ Capital reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • IEQ Capital sold 12,229 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $16.5K.
  • IEQ Capital first reported a position in Zentalis Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • IEQ Capital's Zentalis Pharmaceuticals position peaked at $149K in Q1 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.